HongKong:2105

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...

2024-11-20 22:00 1376

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afureser...

2024-05-23 20:42 1825

Laekna Releases 2023 ESG Report

SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX onJune 29, 2023.  Laekna means "to cure, to heal", underscor...

2024-04-29 20:30 1278

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research...

2024-04-08 08:30 1245

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...

2024-01-04 12:40 1611

2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results

-     A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering -     70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors  -     Demonstrated a confirmed objecti...

2023-12-11 18:55 1375

Laekna, Inc. (2105.HK) Announces Interim Results 2023

* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected in the late fourth quarter of 2023 * For the Phase Ib/III trial of Afuresertib + Fulvestrant ...

2023-08-25 08:00 3484